AspirinAnti-Inflammatory Agents, Non-SteroidalCyclooxygenase InhibitorsCyclooxygenase 2 InhibitorsIbuprofenProstaglandin-Endoperoxide SynthasesDiclofenacNaproxenCyclooxygenase 2Cyclooxygenase 1Platelet Aggregation InhibitorsSulfonamidesPyrazolesSulindacIndomethacinFlurbiprofenEnzyme InhibitorsPiroxicamDose-Response Relationship, DrugIsoenzymesSulfonesNitrobenzenesThromboxane B2AcetaminophenKetoprofenSalicylatesDinoprostoneEtodolacTolmetinLactonesSodium SalicylateThiazinesPlatelet AggregationMolecular StructureStomach UlcerGastrointestinal DiseasesTiclopidineDrug Therapy, CombinationProstaglandinsStereoisomerismGastrointestinal HemorrhageDrug InteractionsKetorolacModels, MolecularPhenylbutazoneAnti-Inflammatory AgentsTime FactorsGrowth Differentiation Factor 15Cyclic Nucleotide Phosphodiesterases, Type 4RolipramCells, CulturedBlood PlateletsMembrane ProteinsStructure-Activity RelationshipPhosphodiesterase InhibitorsAnalgesics, Non-NarcoticPlatelet Function TestsGastric MucosaRisk FactorsFenoprofenRats, WistarDouble-Blind MethodArachidonic AcidDrug Hypersensitivity3',5'-Cyclic-AMP PhosphodiesterasesRats, Sprague-DawleyKineticsAnalgesicsCell Line, TumorApoptosisDrug DesignLipoxygenase InhibitorsAsthma, Aspirin-InducedThiazolesAntineoplastic AgentsTreatment Outcome6-Ketoprostaglandin F1 alphaAdministration, OralAnticarcinogenic AgentsPyridinesPeptic Ulcer HemorrhageChemopreventionIndolesInhibitory Concentration 50Molecular ConformationThromboxanesDiflunisalNitric OxideSignal TransductionIsoxazolesTropaeolaceaeOsteoarthritisThromboxane A2Prospective StudiesWarfarinAnticoagulantsEpoprostenolMagnetic Resonance SpectroscopyNitrilesOxyphenbutazone